8-K: Vir Biotechnology Announces Mixed Results for Hepatitis B Treatment, Shifts Focus to Hepatitis Delta Program

Vir Biotechnology reports preliminary Phase 2 data for its hepatitis B treatment candidates, tobevibart and elebsiran, while streamlining the program and prioritizing its hepatitis delta efforts.

Summary

• Vir Biotechnology announced 24-week post-end of treatment data from its Phase 2 MARCH study evaluating tobevibart and elebsiran, with or without PEG-IFN, for chronic hepatitis B.
• The study showed HBsAg loss in 17% and 21% of participants with low baseline HBsAg receiving tobevibart and elebsiran without or with PEG-IFN, respectively.
• Functional cure was achieved in 11% and 15% of participants with low baseline HBsAg receiving tobevibart and elebsiran without or with PEG-IFN, respectively.
• The company will streamline the final stages of the MARCH Phase 2 study and will not allocate additional resources beyond completing the ongoing Phase 2 study while minimizing cost.
• Vir Biotechnology is prioritizing its ECLIPSE Phase 3 program for chronic hepatitis delta and its dual-masked T-cell engager oncology programs.
• The company reiterates its cash runway guidance into mid-2027 based on the current operating plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are some positive aspects, such as the cash runway and commitment to hepatitis delta, the decision to streamline the hepatitis B program and the need for a partner suggest challenges.

Positives

• The combination of tobevibart and elebsiran showed some efficacy in achieving HBsAg loss and functional cure in a subset of patients with low baseline HBsAg levels.
• The safety and tolerability profile of tobevibart and elebsiran are consistent with prior studies.
• Vir Biotechnology is committed to developing tobevibart and elebsiran for chronic hepatitis delta.
• The company's cash runway extends into mid-2027.

Negatives

• Phase 3 development in chronic hepatitis B will not move forward without a global development and commercialization partner, which has not been secured.
• The company will streamline the final stages of the MARCH Phase 2 study and will not allocate additional resources beyond completing the ongoing Phase 2 study while minimizing cost.
• The HBsAg loss and functional cure rates were relatively low in the overall study population.

Risks

• The company may face challenges in securing a global development and commercialization partner for its chronic hepatitis B program.
• The company's decision to streamline the MARCH Phase 2 study could impact the program's future development.
• The company's focus on chronic hepatitis delta and oncology programs could divert resources from other potential opportunities.
• Unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events, could impact the company's programs.
• Challenges in accessing manufacturing capacity, clinical site activation rates or clinical enrollment rates that are lower than expected, and the timing and outcome of Vir Biotechnologys planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals could impact the company's programs.

Future Outlook

Vir Biotechnology is committed to the continued development of tobevibart and elebsiran in chronic hepatitis delta, based on the transformational potential of the first-of-its-kind investigational combination to achieve complete suppression of the hepatitis delta virus.

Management Comments

• Mark Eisner, MD., MPH, Chief Medical Officer, Vir Biotechnology, stated that the MARCH data demonstrate that combinations of tobevibart and elebsiran can achieve and maintain HBsAg loss in a subset of participants with low baseline HBsAg levels.
• Mark Eisner, MD., MPH, Chief Medical Officer, Vir Biotechnology, stated that these findings provide important insights into the challenges of achieving functional cure in chronic hepatitis B and will inform future development efforts in the field.

Industry Context

The announcement comes amid ongoing efforts to develop effective treatments for chronic hepatitis B, a significant global health challenge. The company's decision to prioritize its hepatitis delta program reflects the growing recognition of the unmet need in this area.

Comparison to Industry Standards

• The reported HBsAg loss and functional cure rates are within the range of other investigational therapies for chronic hepatitis B.
• Gilead Sciences and Assembly Biosciences are also developing treatments for chronic hepatitis B.
• The company's approach of combining tobevibart and elebsiran with or without PEG-IFN is similar to other combination strategies being explored in the field.

Stakeholder Impact

• Shareholders may be concerned about the company's decision to streamline the hepatitis B program.
• Patients with chronic hepatitis delta may benefit from the company's continued development of tobevibart and elebsiran for this indication.
• Employees working on the hepatitis B program may be affected by the company's decision to streamline the program.

Next Steps

• Vir Biotechnology will streamline the final stages of the MARCH Phase 2 study.
• The company will continue to develop tobevibart and elebsiran for chronic hepatitis delta.
• The company will seek a global development and commercialization partner for its chronic hepatitis B program.

Key Dates

Keywords

Vir Biotechnology, tobevibart, elebsiran, chronic hepatitis B, chronic hepatitis delta, HBsAg, functional cure, Phase 2, Phase 3, clinical trial, EASL Congress